What is it? Why is it important?

Risk-Based Monitoring (RBM) requires that the monitoring strategy is adapted based on study risks. Not all studies carry the same risks. Thus, monitoring strategies are adapted accordingly.

Adaptations may include:

  • Monitoring frequency: low-risk studies (i.e. study risk categories) require less monitoring
  • Extent of monitoring: low-risk studies require less data and document checks (e.g. 20% of data versus 80%)
  • Nature of monitoring: with on-site versus Central Data Monitoring. High-risk studies may require more on-site monitoring than low-risk studies

The study SP-INV is responsible to identify study risks (e.g. risk-based approach).

More

RBM should focus on critical data, such as:

  • The Informed Consent (IC) process that provides evidence that all participants have agreed to participate in a study
  • Participant eligibility criteria regarding study participation
  • Data needed to assess the study outcome endpoint or data that could potentially impact the endpoint
  • Study design and intervention
  • Safety documentation that demonstrates compliance with safety reporting procedures (e.g. to SP-INV, Ethics Committee (EC), Regulatory Authorities such as Swissmedic)

What do I need to do?

As a SP-INV, define the monitoring strategy of your study. From a monitoring point of view, the strategy should be risk-based. As a helpful tool, use the SCTO RBM score calculator..

Assess risks-based on:

 

Define thresholds that will trigger measures to reduce risks. Based on risk, the monitoring strategy may be to adapt the number of planned monitoring visits accordingly.

More

When defining the monitoring strategy of the study, consider the following aspects:

  • Vulnerability of participants, complexity of the Participant Information and Consent process, studies in emergency settings
  • Complexity of design (e.g. eligibility criteria, study outcome / endpoint, procedures,…)
  • Lack of safety data or existing safety data that require increase surveillance
  • Intervention complexity (e.g. administration logistics)
  • Number of participating sites (e.g. monocentric versus multicentric in Switzerland, international study)
  • Data complexity (e.g. many variables, extensive data collection and database set-up)

 

The CTU-RBM score calculator lists 22 potential study risks classified in 7 risk-categories, such as risks related to participants, design, safety, intervention, management, data, and others.

Each risk is evaluated on a 3-level risk impact scale (1 = low, 2 = medium, 3 = high), including risk outcome, and risk detectability.

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

External Links

  • ADAMON – Risk-adapted monitoring

References

ICH GCP E6(R2) – see in particular guidelines

  • 4.5 Protocol compliance
  • 4.8 Informed consent of study participants
  • 5.0 Quality management

ISO 14155 Medical Device – see in particular section (access liable to costs)

  • 5.8 Informed consent
  • 5.2 Risk management

Swiss Law

ClinO – see in particular article

  • Art. 2b Definition of intervention
  • Art. 19 - 20 Study categorisation

ClinO-MD – see in particular article

  • Art. 2a Definition of clinical intervention
  • Arr. 2a Definition of performance study

HRO – see in particular article

  • Art. 3a Definition of research
  • Art. 7 Research categorisation

 

Documents

Abbreviations
  • ClinO – Clinical Trials Ordinance
  • CTU – Clinical Trials Unit
  • CTU-RBM – CTU-Risk Based Monitoring
  • EC – Ethics Committee
  • eCRF – electronic Case Report Form
  • HRO – Human Research Ordinance
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ISO – International Organisation for Standardisation
  • IT – Information Technology
  • RA – Regulatory Authorities SAE
  • RBM – Risk Based Monitoring
  • SAE – Serious Adverse Event
  • SOP – Standard Operating Procedure
  • SP-INV – Sponsor-Investigator
Development ↦ Monitoring ↦ Montoring Strategy ↦ Risk-Based Monitoring
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Basic Drug or Device
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Development ↦ Monitoring ↦ Montoring Strategy ↦ Risk-Based Monitoring

Please note: the Easy-GCS tool is currently under construction.